S V Chem Intermediates remains focused on continuously upgrading its quality systems and operational capabilities to meet changing industry expectations
Radha Krishanan, Director
The pharmaceutical industry is witnessing a major shift toward peptide-based therapeutics, creating strong demand for protected amino acids and specialty pharmaceutical intermediates. As advanced therapies gain wider adoption across oncology, diabetes, metabolic disorders, and chronic disease treatment, pharmaceutical companies are increasingly looking for reliable suppliers capable of delivering high-purity building blocks that meet global regulatory and quality standards.
For many years, Indian pharmaceutical manufacturers depended heavily on imports of protected amino acids and peptide intermediates from Europe and the United States. This dependency increased procurement costs, extended delivery timelines, and exposed manufacturers to supply chain uncertainties. With India strengthening its position as a global pharmaceutical manufacturing hub, the need for domestic capabilities in specialty intermediates has become more important than ever.
S V Chem Intermediates has emerged as a focused player in this evolving landscape. Specializing in protected amino acid derivatives and pharmaceutical intermediates, the company is contributing to India’s growing self-reliance in specialty chemical manufacturing while supporting the expanding global peptide therapeutics market.
Built on Pharmaceutical Expertise
The foundation of S V Chem Intermediates is rooted in extensive pharmaceutical research and peptide chemistry experience. The company’s leadership journey began in the 1990s in pharmaceutical R&D, where early exposure to research-driven manufacturing created a strong technical base in specialty chemicals and peptide development.
Further industry experience at leading pharmaceutical organizations, including Sun Pharmaceutical Industries, provided deeper expertise in peptide development, process scale-up, and regulatory filings. During these years, one challenge became increasingly evident, the heavy dependence of Indian pharmaceutical companies on imported protected amino acids and specialty intermediates.
Recognizing this gap in the domestic supply chain, S V Chem Intermediates was established with a clear objective: to manufacture high-quality, cost-effective peptide building blocks within India while maintaining international standards of quality and compliance.
Over the years, the company has steadily developed capabilities aligned with the evolving needs of pharmaceutical and peptide manufacturers. Today, it serves both domestic and international markets with a growing portfolio of protected amino acid derivatives and pharmaceutical intermediates.
Supporting the Expanding Peptide Market
As peptide therapeutics continue gaining importance within modern medicine, the demand for specialized intermediates has increased significantly. Protected amino acids play a critical role in peptide synthesis and advanced drug development, making quality and consistency essential for pharmaceutical manufacturers.
S V Chem Intermediates has aligned its operations with this growing demand through a broad portfolio that includes CBZ, Boc, Fmoc derivatives, amino acid esters, and customized pharmaceutical intermediates. “This diversified product range enables the company to support pharmaceutical organizations across multiple stages of research, development, and manufacturing”, speaks Radha Krishanan, Director.
What differentiates the company is its technical understanding of peptide chemistry and process development. Rather than functioning solely as a raw material supplier, S V Chem Intermediates positions itself as a development-oriented partner capable of providing customized solutions tailored to specific client requirements.
The company’s flexibility and responsiveness have become important advantages in a market where pharmaceutical companies increasingly require shorter development timelines, dependable supply chains, and technically capable manufacturing partners.
S V Chem Intermediates remains focused on continuously upgrading its quality systems and operational capabilities to meet changing industry expectationsRadha Krishanan, Director
Innovation also remains central to the organization’s growth strategy. Over the years, the company has successfully developed more than 200 amino acid products, reflecting its continued focus on process optimization and value-added derivatives. This approach allows S V Chem Intermediates to stay aligned with emerging pharmaceutical trends, particularly in peptide APIs and advanced therapeutic applications.
Focused on Quality and Compliance
In the pharmaceutical intermediates industry, maintaining consistent quality and regulatory compliance is critical. S V Chem Intermediates has built its operations around GMP-compliant manufacturing systems supported by ISO-certified quality processes and stringent operational controls.
The company follows strict quality monitoring procedures across every stage of manufacturing to ensure consistency, purity, and reliability. Its scalable manufacturing infrastructure allows it to meet growing customer requirements while maintaining high production standards.
Successful client audits further reinforce the company’s commitment to globally aligned manufacturing practices. As pharmaceutical regulations continue evolving across international markets, S V Chem Intermediates remains focused on continuously upgrading its quality systems and operational capabilities to meet changing industry expectations.
Beyond manufacturing excellence, the company places strong emphasis on long-term customer relationships built through transparency, technical support, and reliable supply commitments. In an industry frequently challenged by supply chain disruptions, regulatory complexities, and cost pressures, this customer-centric approach has helped strengthen its presence across domestic and international pharmaceutical markets.
Looking ahead, S V Chem Intermediates aims to further expand its product portfolio and manufacturing capabilities while continuing to invest in innovation and process development. With peptide therapeutics expected to play an increasingly important role in the future of healthcare, the company is positioning itself to contribute meaningfully to the next phase of pharmaceutical manufacturing growth.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")